Segment Information - Schedule of Financial Information by Segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenues	$ 17,975,000	$ 21,335,000
Gross profit	(1,690,000)	11,682,000
Direct expenses	144,198,000	159,694,000
Segment contribution	(145,888,000)	(148,012,000)
Indirect expenses	(120,288,000)	(38,953,000)
Loss from operations	(25,600,000)	(109,059,000)
Components of other
Change in fair value of contingent consideration liability	(126,277,000)	(41,145,000)
Change in fair value of contingent stock consideration	186,000
Goodwill impairment	3,610,000
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	75,379,000	85,107,000
Segment contribution	(75,379,000)	(85,107,000)
Biobanking
Segment Reporting Information [Line Items]
Net revenues	5,512,000	5,522,000
Gross profit	1,976,000	1,873,000
Direct expenses	1,699,000	2,119,000
Segment contribution	277,000	(246,000)
Degenerative Disease
Segment Reporting Information [Line Items]
Net revenues	12,463,000	15,813,000
Gross profit	(3,666,000)	9,809,000
Direct expenses	10,859,000	8,450,000
Segment contribution	(14,525,000)	1,359,000
Components of other
Goodwill impairment	3,610,000	0
Other
Segment Reporting Information [Line Items]
Direct expenses	56,261,000	64,018,000
Segment contribution	(56,261,000)	(64,018,000)
Indirect expenses	(120,288,000)	(38,953,000)
Components of other
Change in fair value of contingent consideration liability	(126,277,000)	(41,145,000)
Change in fair value of contingent stock consideration	186,000
Goodwill impairment	3,610,000
Amortization	2,193,000	2,192,000
Total other	$ (120,288,000)	$ (38,953,000)